Zentalis Pharmaceuticals and PureTech Health get Fast Track Designation from FDA for their cancer treatments

gorodenkoff/iStock via Getty Images

• Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced that the FDA has granted Fast Track Designation to azenosertib for treating platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with elevated Cyclin E1 protein levels.
• PureTech Health (NASDAQ:PRTC) also said that the FDA has